Management of high-risk patients with hypertension and left ventricular hypertrophy in Germany: Differences between cardiac specialists in the inpatient and outpatient setting

BMC Public Health

Volumn 6, Issue , 2006, Pages

  Völler, Heinz ^a   Sonntag, Frank J ^b   Thiery, Joachim ^c   Wegscheider, Karl ^d   Luft, Friedrich C ^e   Bestehorn, Kurt ^f,g  

^a Klinik am See   (Germany)

^b Bundesverband Niedergelassener Kardiologen ^*  (Germany)

^c UNIVERSITY HOSPITAL LEIPZIG   (Germany)

^d UNIVERSITY OF HAMBURG   (Germany)

^e CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^f MSD Sharp and Dohme GmbH   (Germany)

^g DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN 1 RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY CARE UNIT; DIABETES MELLITUS; FEMALE; FOLLOW UP; GERMANY; HEALTH CARE MANAGEMENT; HEART LEFT VENTRICLE HYPERTROPHY; HIGH RISK POPULATION; HOSPITAL PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; OUTPATIENT; PREVALENCE; STROKE; AGED; BLOOD PRESSURE MEASUREMENT; CARDIOLOGY; COMORBIDITY; COMPARATIVE STUDY; COMPLICATION; HYPERTROPHY, LEFT VENTRICULAR; MIDDLE AGED; OUTCOME ASSESSMENT; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; PROGNOSIS; PROSPECTIVE STUDY; REHABILITATION CENTER; RISK FACTOR; STANDARDS;

ADULT; AGED; AMBULATORY CARE FACILITIES; BLOOD PRESSURE DETERMINATION; CARDIOLOGY; COMORBIDITY; FEMALE; GERMANY; GUIDELINE ADHERENCE; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; INPATIENTS; MALE; MIDDLE AGED; OUTCOME ASSESSMENT (HEALTH CARE); OUTPATIENTS; PROGNOSIS; PROSPECTIVE STUDIES; REHABILITATION CENTERS; RISK FACTORS;

EID: 33750523197     PISSN: 14712458     EISSN: 14712458     Source Type: Journal    
DOI: 10.1186/1471-2458-6-256     Document Type: Article

References (45)

1. Murray CJ, Lopez AD: Global mortality, disability, and the contribution of risk factors: Global Burden of Disease Study. Lancet 1997, 349(9063):1436-1442.
2. Mathers CD, Sadana R, Salomon JA, Murray CJ, Lopez AD: Healthy life expectancy in 191 countries, 1999. Lancet 2001, 357(9269):1685-1691.
3. Linton MF, Fazio S: A practical approach to risk assessment to prevent coronary artery disease and its complications. Am J Cardiol 2003, 92(1A):19i-26i.
4. Gotto AMJ: How do we achieve optimal cardiovascular risk reduction? Clin Cardiol 2001, 24(8 Suppl):1118-12.
5. Klingbeil AU, Schneider M, Martus P, Messerli FH, Schmieder RE: A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003, 115(1):41-46.
6. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, de Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, Lindholm LH, Nieminen MS, Omvik P, Oparil S, Wedel H: Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002, 359(9311):995-1003.
7. Zidek W, Dusing R, Haller H, Middeke M, Paul M, Schmieder R, Schrader J: New recommendations of the German Hypertension League for the drug treatment of hypertension. Dtsch Med Wochenschr 2003, 128:2468-2469.
8. Guidelines committee: European Society of Hypertension-European Society of Cardiology guidelines for the management of arterial hypertension. J Hypertens 2003, 21:1011-1053.
9. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JLJ, Jones DW, Materson BJ, Oparil S, Wright JTJ, Roccella EJ: The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. JAMA 2003, 289(19):2560-2571.
10. Cabana MD, Rand CS, Powe NR, Wu AW, Wilson MH, Abboud PAC, Rubin HR: Why Don't Physicians Follow Clinical Practice Guidelines?: A Framework for Improvement. JAMA 1999, 282(15):1458-1465.
11. Faulhaber HD, Luft FC: Treatment of high blood pressure in Germany. Am J Hypertens 1998, 11(6 Pt 1):750-753.
12. Sharma AM, Wittchen HU, Kirch W, Pittrow D, Ritz E, Göke B, Lehnert H, Tschöpe D, Krause P, Höfler M, Pfister H, Bramlage P, Unger T: High prevalence and poor control of hypertension in primary care: cross sectional study. J Hypertens 2004, 22:479-486.
13. Wolf-Maier K, Cooper RS, Banegas JR, Giampaoli S, Hense HW, Joffres M, Kastarinen M, Poulter N, Primatesta P, Rodriguez-Artalejo F, Stegmayr B, Thamm M, Tuomilehto J, Vanuzzo D, Vescio F: Hypertension prevalence and blood pressure levels in 6 European countries, Canada, and the United States. J Am Med Ass 2003, 289(18):2363-2369.
14. Nash IS, Nash DB, Fuster V: Do cardiologists do it better? J Am Coll Cardiol 1997, 29(3):475-478.
15. Baessler A, Fischer M, Hengstenberg C, Holmer S, Hubauer U, Huf V, Mell S, Klein G, Riegger G, Schunkert H: [Inpatient rehabilitation improves implementation of therapeutic guidelines for secondary prevention in patients with coronary heart disease]. Z Kardiol 2001, 90(9):646-654.
16. Gubner R, Ungerleider HE: Electrocardiographic criteria of left ventricular hypertrophy. Arch Intern Med 1943, 72:196-209.
17. Sokolow M, Lyon TP: The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 1949, 37:161-186.
18. Levy D, Salomon M, D'Agostino RB, Belanger AJ, Kannel WB: Prognostic implications of baseline electrocardiographic features and their serial changes in subjects with left ventricular hypertrophy. Circulation 1994, 90(4):1786-1793.
19. Devereux RB, Reichek N: Echocardiographic determination of left ventricular mass in man. Anatomic validation of the method. Circulation 1977, 55(4):613-618.
20. Devereux RB, Lutas EM, Casale PN, Kligfield P, Eisenberg RR, Hammond IW, Miller DH, Reis G, Alderman MH, Laragh JH: Standardization of M-mode echocardiographic left ventricular anatomic measurements. J Am Coll Cardiol 1984, 4(6):1222-1230.
21. Diller PM, Smucker DR, David B, Graham RJ: Congestive heart failure due to diastolic or systolic dysfunction. Frequency and patient characteristics in an ambulatory setting. Arch Fam Med 1999, 8(5):414-420.
22. Cleveland WS, Devlin SJ: Locally Weighted Regression. An Approach to Regression Analysis by Local Fitting. J Am Stat Assoc 1988, 83:596-610.
23. Rosenbaum PR, Rubin DB: The central role of the propensity score in observational studies for causal effects. Biometrika 1983, 70:41-55.
24. Rubin DB: Estimating causal effects from large data sets using propensity scores. Ann Intern Med 1997, 127(8 Pt 2):757-763.
25. Mathew J, Sleight P, Lonn E, Johnstone D, Pogue J, Yi Q, Bosch J, Sussex B, Probstfield J, Yusuf S: Reduction of cardiovascular risk by regression of electrocardiographic markers of left ventricular hypertrophy by the angiotensin-converting enzyme inhibitor ramipril. Circulation 2001, 104(14):1615-1621.
26. Dickerson JE, Hingorani AD, Ashby MJ, Palmer CR, Brown MJ: Optimisation of antihypertensive treatment by crossover rotation of four major classes. Lancet 1999, 353(9169):2008-2013.
27. Hasford J, Mimran A, Simons WR: A population-based European cohort study of persistence in newly diagnosed hypertensive patients. J Hum Hypertens 2002, 16(8):569-575.
28. Caro JJ, Salas M, Speckman JL, Raggio G, Jackson JD: Persistence with treatment for hypertension in actual practice. Can Med Assoc J 1999, 160(1):31-37.
29. Law MR, Wald NJ, Morris JK, Jordan RE: Value of low dose combination treatment with blood pressure lowering drugs: analysis of 354 randomised trials. BMJ 2003, 326(7404):1427-1420.
30. Berlowitz DR, Ash AS, Hickey EC, Friedman RH, Glickman M, Kader B, Moskowitz MA: Inadequate management of blood pressure in a hypertensive population. N Engl J Med 1998, 339(27):1957-1963.
31. Myers MG: Compliance in hypertension: Why don't patients take their pills? Can Med Assoc J 1999, 160(1):64-65.
32. Phillips LS, Branch WT, Cook CB, Doyle JP, El-Kebbi IM, Gallina DL, Miller CD, Ziemer DC, Barnes CS: Clinical inertia. Ann Intern Med 2001, 135(9):825-834.
33. Pittrow D, Kirch W, Bramlage P, Lehnert H, Hofler M, Unger T, Sharma AM, Wittchen HU: Patterns of antihypertensive drug utilization in primary care. Eur J Clin Pharmacol 2004, 60(2):135-142.
34. Furstenberg T, Bunzemeier H, Roeder N, Reinecke H: [Cardiovascular medicine in the German diagnosis-related group - (GDRG) system 2005]. Z Kardiol 2005, 94(5):360-370.
35. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S: Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet 1998, 351(9118):1755-1762.
36. Brenner BM, Cooper ME, de Zeeuw D, Keane WF, Mitch WE, Parving HH, Remuzzi G, Snapinn SM, Zhang Z, Shahinfar S, the RENAAL Study Investigators: Effects of Losartan on Renal and Cardiovascular Outcomes in Patients with Type 2 Diabetes and Nephropathy. N Engl J Med 2001, 345(12):861-869.
37. Lewis EJ, Hunsicker LG, Clarke WR, Berl T, Pohl MA, Lewis JB, Ritz E, Atkins RC, Rohde R, Raz I: Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001, 345(12):851-860.
38. Nash IS, Corrato RR, Dlutowski MJ, O'Connor JP, Nash DB: Generalist versus specialist care for acute myocardial infarction. Am J Cardiol 1999, 83(5):650-654.
39. Donohoe MT: Comparing generalist and specialty care: discrepancies, deficiencies, and excesses. Arch Intern Med 1998, 158(15):1596-1608.
40. Schreiber TL, Elkhatib A, Grines CL, O'Neill WW: Cardiologist versus internist management of patients with unstable angina: treatment patterns and outcomes. J Am Coll Cardiol 1995, 26(3):577-582.
41. Chin MH, Friedmann PD, Cassel CK, Lang RM: Differences in generalist and specialist physicians' knowledge and use of angiotensin-converting enzyme inhibitors for congestive heart failure. J Gen Intern Med 1997, 12(9):523-530.
42. Guadagnoli E, Normand SL, DiSalvo TG, Palmer RH, McNeil BJ: Effects of treatment recommendations and specialist intervention on care provided by primary care physicians to patients with myocardial infarction or heart failure. Am J Med 2004, 117(6):371-379.
43. Pearson TA, Peters TD: The treatment gap in coronary artery disease and heart failure: community standards and the post-discharge patient. Am J Cardiol 1997, 80(8B):45H-52H.
44. Fonarow GC: The role of in-hospital initiation of cardioprotective therapies to improve treatment rates and clinical outcomes. Rev Cardiovasc Med 2002, 3 Suppl 3:S2-S10.
45. Anonymous: ASH Specialists Program. Available at http://www.ash-us.org/ specialist_program/index.htm. Last access on 20 September 2006. .